Secured equity financing with gross proceeds of $175M in April 2026Phase 3 clinical trial of denifanstat in moderate to severe acne patients for ...

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 Fi ...

Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to ...

UPADACITINIB acne affected nearly half of surveyed patients with IBD and sometimes changed treatment decisions. Upadacitinib Acne Emerges as Common Real-World Concern. Upadacitini ...

Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead.

If you’ve been dealing with stubborn, unexplainable breakouts recently despite having a solid skincare routine, you might want to take a hard look inside your shaker bottle. Yep. Dermatologists are ...

La Roche-Posay launches a collaboration with Illumination’s Minions & Monsters via a campaign raising awareness, educating on ...

Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne  Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. Javascript is ...

Investors had every reason to suspect today's news from Sagimet Biosciences (SGMT 0.52%) was coming sooner or later.

Skip your standard body wash and choose one with acne-fighting ingredients to combat and prevent breakouts. Shop acne body ...

Hate spending tons of money on skin care? Me too. Save your wallet with these editor-tested summer skin-care dupes that give the expensive brand versions a run for their money.

Sagimet Biosciences Inc. (NASDAQ:SGMT) surged 30% on Monday after unveiling plans to launch a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. during the second half of ...